Covaxin

The Bharat Biotech company said on Friday that the interim analysis of the first and second phase trials of its Covid-19 vaccine ‘Covaxin’ has been successfully completed and now the Phase III trials are being started on 26,000 volunteers.

The Bharat Biotech company on Friday said that the interim analysis of the first and second phase trials of its Covid-19 vaccine ‘Covaxin’ has been successfully completed and now the Phase III trials are being started on 26,000 volunteers.The vaccine manufacturer said in a statement, “After successfully completing the interim analysis of the first and second phase clinical trials of the vaccine ‘Covaxin’, Bharat Biotech is required to conduct the third phase test on 26,000 volunteers at more than 25 centers across India. Approval has been received from the Controller General of Medicine.

Bharat Biotech is developing Covaxin in collaboration with the Indian Council of Medical Research and the National Institute of Viruses. Sources said that the Hyderabad-based vaccine manufacturer had sought permission from the Drug Controller General of India on October 2 to begin the third phase of vaccine testing. In July, the Drug Controller General gave permission to Bharat Biotech to start the first and second phase of clinical trials of the vaccine.

Read this too: https://capitalboat.in/the-opportunity-to-earn-profits-like-irctc-this-stock-sale-is-coming/

Financial & Business News – CapitalBoat
CapitalBoat provides the latest stock market, financial and business news. Get stock market quotes, personal financial advice, corporate news, Startup stories and latest updates on Economy & Politics, Personal Finance on your Whats app.
Get Breaking News Notifications Via Whats app.
Join our whats app newsletter using this invite link. Click on the link to open chat and send message ‘START’ to join us.
https://wa.me/918208416824?text=START

Please forward this message on to your Friends, Colleagues and Family members who may be interested in this.

Leave a Reply

Your email address will not be published. Required fields are marked *